Clinical efficacy of teicoplanin and linezolid for MRSA infections:a comparative study

OBJECTIVE To compare the therapeutic effect and safety of teicoplanin and linezolid used for the treatment of the patients with MRSA infections in ICU.METHODS The open-label control test was performed for 68 patients with MRSA infections was performed,35 cases were treated with teicoplanin for 400mg/per time and 12h once,after 3 doses,once per day;33 patients with MRSA infections were treated with linezolid for 600mg per time,12h once,which were all the intravenous drip with 14-18d a course;the therapeutic effect,bacterial clearance,and APACHEⅡscore before and after the medication between the two groups were compared.RESULTS The clinical effective rates of teicoplanin and linezolid for treatment of severe MRSA infections were 88.6% and 90.9%,respectively(P0.05),the bacterial clearance rates were 86.8% and 88.2%,respectively the differences were not statistically significant;the APACHEⅡscore of the patients on the 14th day were(10.17±3.32) and(13.66±5.98),respectively,the teicoplanin group was superior to the linezolid group,the difference was statistically significant(P0.05);the incidence rates of the adverse reactions were 11.4% and 18.2%,the incidence rate of the adverse reactions was lower in the teicoplanin group than in the linezolid group,the difference was statistically significant(P0.05).CONCLUSION Both teicoplanin and linezolid exhibit a similar clinical efficacy on the treatment of patients with MRSA infections,but the teicoplanin is superior to linezolid in the safety of clinical medication.